MOv-gamma chimeric receptor T cells

MOv-gamma chimeric receptor T cells are autologous or allogeneic T lymphocytes genetically modified with a first-generation chimeric antigen receptor (CAR) derived from the variable domains of the murine monoclonal antibody MOv18, targeting folate-binding protein (also known as folate receptor alpha), which is overexpressed in the majority of human ovarian carcinomas. The CAR consists of the antibody’s single-chain variable region (scFv) fused to the Fc receptor gamma signaling chain. These engineered T cells redirect antigen specificity toward cancer cells expressing folate receptor alpha and mediate tumor cell lysis and cytokine release upon antigen recognition. Preclinical and early-phase clinical studies demonstrated feasibility, immunogenicity, expansion of large numbers of modified T cells, and antitumor activity in murine models and ovarian cancer patients, but limited in vivo persistence was observed. The approach is part of the earliest generation of CAR T-cell therapies, preceding the modern “second generation” CARs with additional costimulatory domains[1][2][3][5].

Other names

MOv-gamma CAR T cellsanti-folate receptor CAR T cells